GB201914747D0 - PD1 and vegfr2 dual-binding agents - Google Patents

PD1 and vegfr2 dual-binding agents

Info

Publication number
GB201914747D0
GB201914747D0 GB201914747A GB201914747A GB201914747D0 GB 201914747 D0 GB201914747 D0 GB 201914747D0 GB 201914747 A GB201914747 A GB 201914747A GB 201914747 A GB201914747 A GB 201914747A GB 201914747 D0 GB201914747 D0 GB 201914747D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
vegfr2
dual
vegfr2 dual
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201914747A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultrahuman Eight Ltd
Original Assignee
Ultrahuman Eight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrahuman Eight Ltd filed Critical Ultrahuman Eight Ltd
Priority to GB201914747A priority Critical patent/GB201914747D0/en
Publication of GB201914747D0 publication Critical patent/GB201914747D0/en
Priority to GBGB2013180.1A priority patent/GB202013180D0/en
Priority to PCT/EP2020/078427 priority patent/WO2021069670A1/en
Priority to KR1020227014433A priority patent/KR20220091490A/ko
Priority to HUE20789105A priority patent/HUE071341T2/hu
Priority to CA3156096A priority patent/CA3156096C/en
Priority to RS20250448A priority patent/RS66837B1/sr
Priority to CA3289307A priority patent/CA3289307A1/en
Priority to PT207891052T priority patent/PT4041763T/pt
Priority to JP2022521074A priority patent/JP7689116B2/ja
Priority to EP25159487.5A priority patent/EP4570824A3/en
Priority to ES20789105T priority patent/ES3027238T3/es
Priority to US17/768,013 priority patent/US20240101674A1/en
Priority to SI202030611T priority patent/SI4041763T1/sl
Priority to EP20789105.2A priority patent/EP4041763B1/en
Priority to AU2020365021A priority patent/AU2020365021A1/en
Priority to CN202080075802.2A priority patent/CN114981301B/zh
Priority to CN202511932691.3A priority patent/CN121758618A/zh
Priority to EP25212556.2A priority patent/EP4671279A2/en
Priority to HRP20250523TT priority patent/HRP20250523T1/hr
Priority to PL20789105.2T priority patent/PL4041763T3/pl
Priority to DK20789105.2T priority patent/DK4041763T3/da
Priority to FIEP20789105.2T priority patent/FI4041763T3/fi
Priority to LTEPPCT/EP2020/078427T priority patent/LT4041763T/lt
Priority to IL292158A priority patent/IL292158A/en
Priority to US19/056,312 priority patent/US12479920B2/en
Priority to JP2025087525A priority patent/JP2025134713A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
GB201914747A 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents Ceased GB201914747D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents
LTEPPCT/EP2020/078427T LT4041763T (lt) 2019-10-11 2020-10-09 Pd1 ir vegfr2 dvigubo surišimo agentai
US17/768,013 US20240101674A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
AU2020365021A AU2020365021A1 (en) 2019-10-11 2020-10-09 PD1 and VEGFR2 dual-binding agents
HUE20789105A HUE071341T2 (hu) 2019-10-11 2020-10-09 PD1 és VEGFR2 kettõs kötõszerek
CA3156096A CA3156096C (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
RS20250448A RS66837B1 (sr) 2019-10-11 2020-10-09 Agensi sa dvostrukim vezivanjem za pd1 i vegfr2
CA3289307A CA3289307A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
PT207891052T PT4041763T (pt) 2019-10-11 2020-10-09 Agentes de ligação dual a pd1 e vegfr2
JP2022521074A JP7689116B2 (ja) 2019-10-11 2020-10-09 Ｐｄ１およびｖｅｇｆｒ２二重結合剤
EP25159487.5A EP4570824A3 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
ES20789105T ES3027238T3 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
PCT/EP2020/078427 WO2021069670A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
SI202030611T SI4041763T1 (sl) 2019-10-11 2020-10-09 Dvojna veziva PD1 in VEGFR2
EP20789105.2A EP4041763B1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
KR1020227014433A KR20220091490A (ko) 2019-10-11 2020-10-09 Pd1 및 vegfr2 이중 결합제
CN202080075802.2A CN114981301B (zh) 2019-10-11 2020-10-09 Pd1和vegfr2双结合剂
CN202511932691.3A CN121758618A (zh) 2019-10-11 2020-10-09 Pd1和vegfr2双结合剂
EP25212556.2A EP4671279A2 (en) 2019-10-11 2020-10-09 DUAL LIAISON OFFICERS PD1 AND VEGFR2
HRP20250523TT HRP20250523T1 (hr) 2019-10-11 2020-10-09 Pd1 i vegfr2 sredstva za dvostruko vezivanje
PL20789105.2T PL4041763T3 (pl) 2019-10-11 2020-10-09 Dualne środki wiążące pd1 i vegfr2
DK20789105.2T DK4041763T3 (da) 2019-10-11 2020-10-09 Pd1- og vegfr2-dobbeltbindende midler
FIEP20789105.2T FI4041763T3 (fi) 2019-10-11 2020-10-09 Pd1:tä ja vegfr2:ta kaksoissitovia aineita
IL292158A IL292158A (en) 2019-10-11 2022-04-11 The agent that binds both vegfr2 and pd1
US19/056,312 US12479920B2 (en) 2019-10-11 2025-02-18 PD1 and VEGFR2 dual-binding agents
JP2025087525A JP2025134713A (ja) 2019-10-11 2025-05-26 Ｐｄ１およびｖｅｇｆｒ２二重結合剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents

Publications (1)

Publication Number Publication Date
GB201914747D0 true GB201914747D0 (en) 2019-11-27

Family

ID=68619556

Family Applications (2)

Application Number Title Priority Date Filing Date
GB201914747A Ceased GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A Ceased GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2013180.1A Ceased GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents

Country Status (20)

Country Link
US (2) US20240101674A1 (https=)
EP (3) EP4041763B1 (https=)
JP (2) JP7689116B2 (https=)
KR (1) KR20220091490A (https=)
CN (2) CN114981301B (https=)
AU (1) AU2020365021A1 (https=)
CA (2) CA3289307A1 (https=)
DK (1) DK4041763T3 (https=)
ES (1) ES3027238T3 (https=)
FI (1) FI4041763T3 (https=)
GB (2) GB201914747D0 (https=)
HR (1) HRP20250523T1 (https=)
HU (1) HUE071341T2 (https=)
IL (1) IL292158A (https=)
LT (1) LT4041763T (https=)
PL (1) PL4041763T3 (https=)
PT (1) PT4041763T (https=)
RS (1) RS66837B1 (https=)
SI (1) SI4041763T1 (https=)
WO (1) WO2021069670A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CN116143935A (zh) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 重组抗体及其应用
WO2024032662A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 一种靶向pd-1和vegf的抗体及其应用
CN118620082A (zh) * 2023-03-10 2024-09-10 南京维立志博生物科技有限公司 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RU2689760C2 (ru) * 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
TWI822897B (zh) 2018-11-06 2023-11-21 大陸商江蘇恆瑞醫藥股份有限公司 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents

Also Published As

Publication number Publication date
PT4041763T (pt) 2025-05-16
EP4570824A2 (en) 2025-06-18
EP4671279A2 (en) 2025-12-31
EP4570824A3 (en) 2025-06-25
CN121758618A (zh) 2026-03-31
DK4041763T3 (da) 2025-05-19
RS66837B1 (sr) 2025-06-30
US20250243276A1 (en) 2025-07-31
AU2020365021A1 (en) 2022-05-26
JP7689116B2 (ja) 2025-06-05
US12479920B2 (en) 2025-11-25
SI4041763T1 (sl) 2025-08-29
WO2021069670A1 (en) 2021-04-15
KR20220091490A (ko) 2022-06-30
CN114981301A (zh) 2022-08-30
CA3289307A1 (en) 2026-03-02
EP4041763B1 (en) 2025-02-26
HUE071341T2 (hu) 2025-08-28
JP2025134713A (ja) 2025-09-17
HRP20250523T1 (hr) 2025-07-04
EP4041763A1 (en) 2022-08-17
ES3027238T3 (en) 2025-06-13
GB202013180D0 (en) 2020-10-07
LT4041763T (lt) 2025-06-10
CA3156096A1 (en) 2021-04-15
IL292158A (en) 2022-06-01
FI4041763T3 (fi) 2025-05-15
US20240101674A1 (en) 2024-03-28
PL4041763T3 (pl) 2025-07-07
JP2022553908A (ja) 2022-12-27
CN114981301B (zh) 2026-04-14
CA3156096C (en) 2026-03-17

Similar Documents

Publication Publication Date Title
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
IL292692B1 (en) Mrgprx2 antagonists and their uses
ZA202002172B (en) Pde9 inhibitor and use thereof
IL292158A (en) The agent that binds both vegfr2 and pd1
SG11202004877UA (en) Sulfonamide compounds and use thereof
IL282350A (en) Bernani-RGMC inhibitors and their use
HUE059778T2 (hu) URAT1-inhibitor és alkalmazása
SG11202008246VA (en) Pd1 binding agents
GB2591554B (en) Composiitons and methods and uses relating thereto
IL277131A (en) PD1 binding factors
IL277749A (en) Palladianolide compounds and their use
IL287503A (en) Thio-semicarbazide compounds and their use
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
IL282527A (en) 5-Azaindazole history and their use
IL282526A (en) 5-Azaindazole history and their use
GB2589437B (en) Circuitry and methods
IL288828A (en) Binding factors - cd38 and their use
IL280369A (en) Myokines and their uses
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
IL278919A (en) Combinations comprising tropifexor and cenicriviroc
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB2561945B (en) Tissue stain and use thereof
GB201714510D0 (en) Prothesis and othosis
GB201902266D0 (en) New methods and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)